People default image

Jenny Wong PhD

Senior Associate
About

With Jenny, clients benefit from the rare combination of scientific depth and legal precision, guided by a trusted advisor who understands the complexities of innovation from the inside out.

With a focus on complex, multi-jurisdictional patent litigation, Jenny's practice is underpinned by a PhD in biochemistry and molecular biology, and five years of postdoctoral research in neuroscience at two of Australia’s leading research institutions.

Jenny brings this scientific rigour to her legal work, focusing on life sciences patent disputes before the Federal Court of Australia and the Australian Patent Office. She has acted in matters involving human vaccines, monoclonal antibodies, gene editing technologies, transgenic mouse models, and small molecule pharmaceuticals. Her clients - ranging from global pharmaceutical companies to cutting-edge biotech innovators - value her ability to distil complex technical issues into clear, strategic legal advice.

In addition to litigation, Jenny advises on freedom to operate, pricing, and reimbursement issues for prescription pharmaceuticals in Australia, helping clients navigate the regulatory and commercial landscape with confidence.

Known for her calm, considered approach and deep commitment to her clients’ goals, Jenny is a trusted partner in high-stakes matters. Her ability to bridge the gap between science and law makes her an invaluable asset to clients operating at the forefront of innovation.

Professional QualificationsSolicitor of the High Court of AustraliaSolicitor of the Supreme Court of New South Wales

EXPERIENCE

  • Acted for a global biopharmaceutical company in the Australian arm of a multijurisdictional patent dispute. Acted in a patent infringement and revocation proceeding in the Federal Court in relation to patents covering pneumococcal conjugate vaccine compositions. The decision arising from this case was the first in Australia to provide detailed judicial consideration of the new support requirement for Australian patents.*
  • Acted for a global biopharmaceutical company in the Australian arm of a multi-jurisdictional patent dispute. Acted in an opposition in the Australian Patent Office to oppose the grant of a patent application to a method of treating ulcerative colitis. In parallel, in the Federal Court, acted in patent infringement and revocation proceedings concerning divisional innovation patents claiming the method of treatment.*
  • Advised a global originator company in relation to a patent dispute concerning a monoclonal antibody used for the treatment of various inflammatory disorders.*
  • Advised a global biopharmaceutical company in relation to a patent dispute concerning a monoclonal antibody used for the treatment of breast and stomach cancers.*
  • Acted for a global biopharmaceutical company in a patent infringement and rectification proceeding in relation to the company's patent covering sitagliptin, the active ingredient in the anti-diabetic medication, Januvia®.*
  • Acted for a global biopharmaceutical company in a patent infringement and revocation proceeding in relation to multiple patents covering lenalidomide, the active ingredient in Revlimid® which is used to treat myeloma.*
  • Acted for a global biopharmaceutical company in the Federal Court and Full Federal Court in a patent infringement and revocation proceeding regarding patents for the treatment of multiple sclerosis. The decision arising from this case established as legal precedent that evidence from multiple experts will be excluded if in substance the evidence is duplicative.*
  • Acted for a global biopharmaceutical company in a patent infringement and rectification proceeding concerning patents to formulations of a GLP-1 agonist. The rectification action involved a challenge to the validity of the extension of term of the patent. The decision arising from this case confirmed that claims to a formulation are eligible for term extension.*
  • Acted for an Australian pharmaceutical company in a patent infringement, revocation and rectification proceeding in relation to patents covering abuse resistant oral controlled release compositions containing oxycodone and naloxone for the treatment of pain.*
  • Acted for a global biopharmaceutical company in a Federal Court appeal from a successful opposition to the grant of the company's patent relating to CRISPR technology in targeted gene editing in eukaryotic cells.*
  • Acted for a global biopharmaceutical company in an appeal to the Federal Court a Patent Office opposition in relation to the company's patent relating to transgenic mouse technology.*
  • Advised and acted for a global biopharmaceutical company in a patent revocation proceeding in relation to patents covering prefilled syringes.*
  • Acted for an Australian mining company in a patent infringement and revocation proceeding in relation to a patent covering autonomous drill rig systems and methods.*
  • Acted for a UK concrete engineering company in patent entitlement proceedings regarding patents to methods of cathodic protection of steel reinforcement in concrete structures. Also acted in costs recovery proceedings following judgment.*
  • Acted for a global photovoltaic manufacturer in a patent infringement and revocation proceeding in relation to a patent covering passivation technology.*

*Denotes experience gained at previous firm.

Education
  • Bachelor of Science (Honours Class I), Biochemistry and Molecular Biology, University of New South Wales
  • Doctor of Philosophy (PhD), Biochemistry and Molecular Biology, University of New South Wales
  • Juris Doctor (JD), University of New South Wales

Memberships and Affiliations

  • Intellectual Property Society of Australia and New Zealand